NOD

Akston Biosciences' AKS-107 Study Published in Frontiers in Immunology, Displaying Ambifect® Platform’s Versatility

Retrieved on: 
Monday, March 11, 2024
Biotechnology, Manufacturing, Diabetes, Health, Pharmaceutical, Research, Other Manufacturing, Infectious Diseases, Science, Veterinary, Clinical Trials, MERS, NOD, Atopic dermatitis, Insulin, Immune tolerance, CGMP, Epitope, Mouse, Immunoglobulin G, Chronic pain, Protein, Infection, Vaccination, Immune system, Nerve growth factor, Notifiable disease, Dengue fever, Vaccine

The study demonstrated AKS-107's potential to target and delete insulin-specific B cells, which are implicated in the development of Type 1 Diabetes (T1D).

Key Points: 
  • The study demonstrated AKS-107's potential to target and delete insulin-specific B cells, which are implicated in the development of Type 1 Diabetes (T1D).
  • AKS-107 is a human IgG1 Fc-fusion protein engineered to retain conformational insulin epitopes that bind to B cell receptors while preventing binding to the insulin metabolic receptor.
  • Regarding its Animal Health applications, Akston is partnered with Dechra Pharmaceuticals PLC to commercialize canine and feline ultra-long insulins.
  • Akston Biosciences Corporation is dedicated to accelerating the next revolution in Animal Health by inventing, developing, and manufacturing breakthrough protein therapeutics for veterinary use.

U.S. FORECLOSURE ACTIVITY CONTINUES TO SEE AN ANNUAL INCREASE

Retrieved on: 
Tuesday, March 12, 2024
REO, Database, NOD, NFS, Real estate owned, LIS, Housing, File, NTS, Foreclosure, Maid service

IRVINE, Calif., March 12, 2024 /PRNewswire/ -- ATTOM, a leading curator of land, property, and real estate data, today released its February 2024 U.S. Foreclosure Market Report, which shows there were a total of 32,938 U.S. properties with foreclosure filings — default notices, scheduled auctions or bank repossessions – down 1 percent from last month but up 8 percent from a year ago.

Key Points: 
  • "The annual uptick in U.S. foreclosure activity hints at shifting dynamics within the housing market," said Rob Barber, CEO at ATTOM.
  • Highest foreclosure rates in South Carolina, Delaware, and Florida
    Nationwide, one in every 4,279 housing units had a foreclosure filing in February 2024.
  • Those states that saw the greatest number of foreclosures starts in February 2024 included: Florida (2,732 foreclosure starts); California (2,730 foreclosure starts); Texas (2,694 foreclosure starts); New York (1,289 foreclosure starts); and Ohio (1,097 foreclosure starts).
  • Among those major metropolitan statistical areas with a population of at least 200,000, those with the greatest number of foreclosure starts in February 2024, included: New York, NY (1,367 foreclosure starts); Houston, TX (998 foreclosure starts); Los Angeles, CA (808 foreclosure starts); Chicago, IL (792 foreclosure starts); and Miami, FL (777 foreclosure starts).

AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development

Retrieved on: 
Thursday, March 7, 2024
Bias, Lung compliance, NON, SCIENCE, Tracheotomy, Acute myeloid leukemia, Mast cell activation syndrome, BTK, Alzheimer's disease, ANCOVA, Azacitidine, Missionary, B cell, Riluzole, CHMP, Guideline, NOD, Sickle cell disease, ALZ, Tablet, MECOM, AML, SCD, Biomarker, DSM-IV codes, Survival, Science, Prostate cancer, Oxygen, EMA, Docetaxel, Health Canada, ISM, FDA, Masitinib, Euronext, Cell, Chromosome abnormality, OS, UPDATE, Multiple sclerosis, COVID-19, Patient, Disease, Itch, RHU, CAFS, Failure, Depression, Pharmaceutical industry

SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT

Key Points: 
  • SUMMARY OF THE WEBCAST HELD ON MARCH 4, 2024 PROVIDING AN UPDATE ON AB SCIENCE DEVELOPMENT
    AB Science SA (Euronext - FR0010557264 - AB) is providing a summary of the live webcast held on March 4, 2024, giving an update on AB Science development.
  • Regarding Health Canada, a Notice of Deficiency-Withdrawal (NOD/w) has been issued and AB Science intends to submit a Request for Reconsideration.
  • Based on the supporting arguments and counterarguments outlined above, AB Science intends to submit a Request for Reconsideration.
  • AB Science will be free to continue the development of masitinib in SCD based on phase 2 data with biomarkers.

SPECIAL REPORT: U.S. COMMERCIAL FORECLOSURES INCREASE IN JANUARY 2024

Retrieved on: 
Thursday, February 22, 2024
Foreclosure, NFS, COVID-19, NOD, REO, Real estate owned, LIS, NTS

IRVINE, Calif., Feb. 22, 2024 /PRNewswire/ -- ATTOM, a leading curator of land, property, and real estate data, today released a special report on U.S. Commercial Foreclosures. The report reveals a significant climb in commercial foreclosures over the years, from a low of 141 in May 2020 to the current figure of 635 in January 2024. This represents a steady increase throughout the period.

Key Points: 
  • Commercial Foreclosures Increase 17 Percent from Last Month and 97 Percent from Last Year; States with the Most Commercial Foreclosures in January 2024 Included California, New York and Texas
    IRVINE, Calif., Feb. 22, 2024 /PRNewswire/ -- ATTOM , a leading curator of land, property, and real estate data , today released a special report on U.S. Commercial Foreclosures.
  • The report reveals a significant climb in commercial foreclosures over the years, from a low of 141 in May 2020 to the current figure of 635 in January 2024.
  • By January 2024, commercial foreclosures had surged to 635, a stark contrast to the 2020 low.
  • By January 2024, California had the highest number of commercial foreclosures for the month, at 181.

U.S. FORECLOSURE ACTIVITY SEES NOTABLE INCREASE IN JANUARY 2024

Retrieved on: 
Tuesday, February 13, 2024
Foreclosure, File, Database, NFS, NOD, Real estate owned, REO, LIS, Housing, NTS, Maid service

IRVINE, Calif., Feb. 13, 2024 /PRNewswire/ -- ATTOM, a leading curator of land, property, and real estate data, today released its January 2024 U.S. Foreclosure Market Report, which shows there were a total of 33,270 U.S. properties with foreclosure filings — default notices, scheduled auctions or bank repossessions – up 5 percent from a year ago, and up 10 percent from the prior month.

Key Points: 
  • We remain vigilant in monitoring these trends to understand their full impact on foreclosure activity."
  • Highest foreclosure rates in Delaware, Nevada, and Indiana
    Nationwide one in every 4,236 housing units had a foreclosure filing in January 2024.
  • Those states that saw the greatest number of foreclosures starts in January 2024 included: California (2,719 foreclosure starts); Texas (2,613 foreclosure starts); Florida (2,330 foreclosure starts); New York (1,341 foreclosure starts); and Illinois (913 foreclosure starts).
  • Among those major metropolitan statistical areas with a population of at least 200,000, those with the greatest number of foreclosure starts in January 2024, included: New York, NY (1,470 foreclosure starts); Houston, TX (1,015 foreclosure starts); Los Angeles, CA (817 foreclosure starts); Miami, FL (804 foreclosure starts); and Chicago, IL (763 foreclosure starts).

U.S. FORECLOSURE ACTIVITY INCREASES FROM 2022 BUT STILL BELOW PRE-PANDEMIC LEVELS

Retrieved on: 
Thursday, January 11, 2024
NOD, Real estate owned, Database, NFS, NTS, Metro, Housing, Silver, Foreclosure, REO, File, LIS

IRVINE, Calif., Jan. 11, 2024 /PRNewswire/ -- ATTOM, a leading curator of land, property, and real estate data, today released its Year-End 2023 U.S. Foreclosure Market Report, which shows foreclosure filings— default notices, scheduled auctions and bank repossessions — were reported on 357,062 U.S. properties in 2023, up 10 percent from 2022 and up 136 percent from 2021 but down 28 percent from 2019, before the pandemic shook up the market. Foreclosure filings in 2023 were also down 88 percent from a peak of nearly 2.9 million in 2010.

Key Points: 
  • Foreclosure filings in 2023 were also down 88 percent from a peak of nearly 2.9 million in 2010.
  • "Reflecting on 2023, we see the recent rise in foreclosure activity as a market correction rather than a cause for alarm.
  • "Our data suggests that while foreclosure activity may fluctuate, it's unlikely to approach the highs seen in the last decade.
  • Instead, we foresee a market that is more reflective of broader economic trends, with foreclosure filings becoming a more predictable aspect of the housing landscape.

PRIDE Industries Recognized by the National Organization on Disability as a 2023 Leading Disability Employer

Retrieved on: 
Tuesday, October 10, 2023
Climate, Tracker, NOD, Employment, Organization, Culture, National Organization of Social Security Claimants' Representatives, Workforce, Environment, Nursing, Disability

New York, NY, Oct. 10, 2023 (GLOBE NEWSWIRE) -- PRIDE Industries has just been named a 2023 Leading Disability Employer by the National Organization on Disability (NOD), earning the right to display the NOD Leading Disability Employer Seal .

Key Points: 
  • New York, NY, Oct. 10, 2023 (GLOBE NEWSWIRE) -- PRIDE Industries has just been named a 2023 Leading Disability Employer by the National Organization on Disability (NOD), earning the right to display the NOD Leading Disability Employer Seal .
  • This important recognition, given once a year, spotlights the transformative contributions made by business leaders in promoting employment opportunities for individuals with disabilities.
  • It also honors those organizations that prioritize diversity, equity, and importantly, accessibility, setting a high standard for others to follow.
  • “As the nation’s leading employer of people with disabilities, we are honored to once again be recognized by the National Organization on Disability,” said Jeff Dern, President and CEO of PRIDE Industries.

Old National Bank Recognized as 2023 Leading Disability Employer

Retrieved on: 
Thursday, October 5, 2023
National Disability Employment Awareness Month, Tracker, NOD, Organization, Equity, National Organization of Social Security Claimants' Representatives, Workforce, Environment, Old National Bank, Creative industries, Disability

In its ninth year, the NOD Leading Disability Employer Seal spotlights the transformative contributions made by business leaders in promoting employment opportunities for individuals with disabilities. It also honors those organizations that prioritize diversity, equity and importantly, accessibility -- setting a high standard for others to follow.

Key Points: 
  • EVANSVILLE, Ind., Oct. 05, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ONB) – Honoring National Disability Employment Awareness Month in October, the National Organization on Disability (NOD) named Old National Bank as one of only 65 Leading Disability Employers for 2023.
  • In its ninth year, the NOD Leading Disability Employer Seal spotlights the transformative contributions made by business leaders in promoting employment opportunities for individuals with disabilities.
  • "Organizations like Old National Bank understand that by harnessing the talents of people with disabilities, they reap the benefits of a more innovative, diverse and dedicated workforce,” said NOD President Carol Glazer.
  • “Actively seeking and championing diversity within our workforce is critical to our success, and annually makes us an employer of choice,” says Corliss Garner, Chief Diversity, Equity and Inclusion Officer, Old National Bank.

AVM Biotechnology Selected by the National Cancer Institute to Present at Bio Investor Forum 2023

Retrieved on: 
Monday, September 11, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NIDDK, Pancreatic cancer, Human, Drug development, NOD, Bio, SBIR, Bone marrow, NHL, National Institutes of Health, Clinical trial, Cancer, Multimedia, Research, Natural killer T cell, National Cancer Institute, Type 1, AVM, Patient, Adoptive cell transfer, Animal, Growth, FDA, NCI, Service, Safety, Pharmaceutical industry, Vaccine, TCR

With a solid pipeline behind AVM0703, AVM Biotechnology is well positioned for significant growth in 2023-2024.

Key Points: 
  • With a solid pipeline behind AVM0703, AVM Biotechnology is well positioned for significant growth in 2023-2024.
  • (Graphic: Business Wire)
    In June 2023, AVM Biotechnology was selected as a 2023-2024 National Cancer Institute (NCI) Showcase Company for their Small Business Innovation Research (SBIR) Investor Initiatives.
  • AVM Biotechnology has previously been awarded five (5) highly competitive National Institute of Health SBIR grants; three (3) of these from the National Cancer Institute.
  • AVM Biotechnology is a clinical stage company headquartered in Seattle, WA developing immunomodulatory therapies for hematological cancer, infectious and autoimmune diseases.

New secondary analysis of CLEAR Outcomes data for bempedoic acid show significant risk reduction of total cardiovascular events and no increase of new-onset diabetes in patients at high-risk of cardiovascular disease

Retrieved on: 
Saturday, August 26, 2023
Diabetes, Health, Pharmaceutical, Clinical Trials, Cardiology, Medical Affairs Bureau, CV, Myocardial infarction, NOD, Bempedoic acid, ATP, Cardiovascular disease, European Society of Cardiology, RRR, CVD, Agent handling, Congress, Incidence, Public health, Blood, Data analysis, Patient, Risk, Daiichi Sankyo, ESC, ACL, Death, Imperial College London, Glycated hemoglobin, Pharmaceutical industry, Dietary supplement

The results, presented at the European Society of Cardiology (ESC) Congress 2023, further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular (CV) events and demonstrate particular benefit in those with diabetes.

Key Points: 
  • The results, presented at the European Society of Cardiology (ESC) Congress 2023, further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular (CV) events and demonstrate particular benefit in those with diabetes.
  • “Furthermore, the data show that treatment with bempedoic acid does not impact HbA1c levels or the incidence of new-onset diabetes.
  • This is particularly important given diabetes patients’ increased risk of a CV event regardless of the presence or not of CVD.
  • These findings reinforce bempedoic acid as an effective treatment option for LDL-C lowering and CV risk reduction in Europe.